If higher insulin levels are associated with higher levels of inflammation, using therapies such as SGLT-2s that acutely decrease insulin levels and GLP-1s that may decrease insulin levels over time, while simultaneously lowering glucose levels, should be recommended for obese people with T2DM if additional pharmacotherapy is needed in addition to, or in place of, metformin. This evidence concerns the gene INS and type 2 diabetes mellitus.